{"id":745626,"date":"2018-12-17T06:30:00","date_gmt":"2018-12-17T06:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\/"},"modified":"2025-11-07T01:26:50","modified_gmt":"2025-11-07T06:26:50","slug":"european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\/","title":{"rendered":"European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma"},"content":{"rendered":"<p class=\"bwalignc\">       European Approval Based on Significant Recurrence-Free Survival        Benefit Demonstrated with KEYTRUDA in the Pivotal Phase 3        EORTC1325\/KEYNOTE-054 Trial     <\/p>\n<p class=\"bwalignc\">       First Approval for KEYTRUDA in an Adjuvant Setting in the European        Union     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the European Commission has approved KEYTRUDA, the<br \/>\n      company\u2019s anti-PD-1 therapy, for the adjuvant treatment of adults with<br \/>\n      stage III melanoma and lymph node involvement who have undergone<br \/>\n      complete resection. This approval is based on data from the pivotal<br \/>\n      Phase 3 EORTC1325\/KEYNOTE-054 trial, conducted in collaboration with the<br \/>\n      European Organisation for Research and Treatment of Cancer (EORTC). An<br \/>\n      updated recurrence-free survival (RFS) data analysis, conducted at the<br \/>\n      request of the European Medicines Agency, demonstrated that KEYTRUDA<br \/>\n      significantly prolonged RFS, reducing the risk of disease recurrence or<br \/>\n      death by 44 percent compared to placebo in the overall population of<br \/>\n      patients with resected, high-risk stage III melanoma (HR=0.56; 98% CI,<br \/>\n      0.44-0.72; p&lt;0.0001).\n    <\/p>\n<p>\n      \u201cMerck\u2019s long-term commitment to melanoma patients includes a particular<br \/>\n      focus on bringing new treatment options to these patients earlier in the<br \/>\n      treatment paradigm,\u201d said Dr. Scot Ebbinghaus, vice president, clinical<br \/>\n      research, Merck Research Laboratories. \u201cThis approval, which is the<br \/>\n      first for KEYTRUDA in the adjuvant setting in the European Union, builds<br \/>\n      upon the foundation established by KEYTRUDA in the advanced and<br \/>\n      metastatic melanoma settings.\u201d\n    <\/p>\n<p>\n      The approval allows marketing of KEYTRUDA in this new indication in all<br \/>\n      28 EU member states plus Iceland, Lichtenstein and Norway, at the<br \/>\n      approved dose of 200 mg every three weeks until disease recurrence,<br \/>\n      unacceptable toxicity, or for a duration of up to one year. KEYTRUDA is<br \/>\n      also approved in Europe as a monotherapy for the treatment of advanced<br \/>\n      (unresectable or metastatic) melanoma in adults.\n    <\/p>\n<p>\n      \u201cMelanoma patients, particularly those with stage III disease, often<br \/>\n      have a high risk of recurrence, and the collaborative study from EORTC<br \/>\n      and Merck demonstrated a significant reduction in the risk of cancer<br \/>\n      returning after surgery,\u201d said Dr. Alexander Eggermont, study chair,<br \/>\n      Director General at the Gustave Roussy Cancer Institute, Professor of<br \/>\n      Oncology, University of Paris-Saclay. \u201cThis approval in the adjuvant<br \/>\n      setting marks another important milestone in the treatment of melanoma.\u201d\n    <\/p>\n<p>\n      <b>Data Supporting the Approval<\/b>\n    <\/p>\n<p>\n      The approval was based on data from the EORTC1325\/KEYNOTE-054 trial, a<br \/>\n      Phase 3, multicenter, randomized, double-blind, placebo-controlled study<br \/>\n      sponsored by Merck and conducted in collaboration with the EORTC. The<br \/>\n      study is evaluating adjuvant therapy with KEYTRUDA compared to placebo<br \/>\n      in patients with completely resected melanoma (stage IIIA [&gt;1 mm lymph<br \/>\n      node metastasis], IIIB or IIIC according to American Joint Committee on<br \/>\n      Cancer (AJCC) 7<sup>th<\/sup> edition). In total, the study enrolled<br \/>\n      1,019 adult patients who were randomly assigned (1:1) to receive either<br \/>\n      an intravenous infusion of KEYTRUDA 200 mg (n=514) or placebo (n=505)<br \/>\n      every three weeks for up to one year until disease recurrence or<br \/>\n      unacceptable toxicity. Co-primary endpoints were RFS for all patients<br \/>\n      and RFS in patients whose tumors express PD-L1. Recurrence-Free Survival<br \/>\n      was defined as the time from randomization until the date of first<br \/>\n      recurrence (local, regional or distant metastasis) or death, whichever<br \/>\n      occurred first.\n    <\/p>\n<p>\n      In the updated analysis of data, with an additional 7 months of<br \/>\n      follow-up in comparison to the initial data cut off from the<br \/>\n      EORTC1325\/KEYNOTE-054 trial, KEYTRUDA significantly prolonged RFS,<br \/>\n      reducing the risk of disease recurrence or death by 44 percent compared<br \/>\n      to placebo in the overall study population (HR=0.56; 98% CI, 0.44-0.72;<br \/>\n      p&lt;0.0001). In the overall intent-to-treat population, the 12-month RFS<br \/>\n      rate was 76 percent in the KEYTRUDA group and 61 percent in the placebo<br \/>\n      group. At 18 months, the RFS rates were 72 percent and 54 percent,<br \/>\n      respectively.\n    <\/p>\n<p>\n      Based on the previously reported final RFS analysis, for the co-primary<br \/>\n      endpoint of RFS in patients with PD-L1 positive tumors (n=853), KEYTRUDA<br \/>\n      demonstrated significantly prolonged RFS, resulting in a reduced risk of<br \/>\n      recurrence or death of 46 percent (HR=0.54; 95% CI, 0.42-0.69) compared<br \/>\n      to placebo. The 6-month RFS rate was 84 percent in the KEYTRUDA group<br \/>\n      and 75 percent in the placebo group. In addition to analysis of patients<br \/>\n      whose tumors express PD-L1, pre-defined subgroup analyses were performed<br \/>\n      in patients whose tumors were PD-L1 negative, BRAF mutation positive or<br \/>\n      BRAF mutation negative, and according to stage. The RFS benefit was<br \/>\n      demonstrated regardless of BRAF mutation status, PD-L1 status, or stage<br \/>\n      (according to AJCC 7<sup>th<\/sup> edition). A post-hoc subgroup analysis<br \/>\n      was performed based on stage according to AJCC 8<sup>th<\/sup> edition,<br \/>\n      but there is limited data on subjects with Stage IIIA according to AJCC 8<sup>th<\/sup><br \/>\n      edition.\n    <\/p>\n<p>\n      Also based on final RFS analysis, in patients with BRAF positive tumors<br \/>\n      (n=507), the 6-month RFS rate was 83 percent in the KEYTRUDA group and<br \/>\n      73 percent in the placebo group. For this patient population, the RFS<br \/>\n      was significantly longer, resulting in a reduced risk of recurrence or<br \/>\n      death of 51 percent with KEYTRUDA (HR=0.49; 95% CI, 0.36-0.67) compared<br \/>\n      to placebo. This RFS benefit demonstrated with KEYTRUDA monotherapy was<br \/>\n      consistent in patients with BRAF-negative tumors.\n    <\/p>\n<p>\n      The safety of KEYTRUDA as monotherapy has been evaluated in 4,948<br \/>\n      patients with advanced melanoma, resected Stage III melanoma (adjuvant<br \/>\n      therapy), non-small cell lung cancer, classical Hodgkin lymphoma,<br \/>\n      urothelial carcinoma, or head and neck squamous cell carcinoma across<br \/>\n      four doses (2 mg\/kg every 3 weeks, 200 mg every 3 weeks, or 10 mg\/kg<br \/>\n      every 2 or 3 weeks) in clinical studies. In this patient population, the<br \/>\n      median observation time was 7.3 months (range: 1 day to 31 months) and<br \/>\n      the most frequent adverse reactions with KEYTRUDA were fatigue (34.1%),<br \/>\n      rash (22.7%), nausea (21.7%) and diarrhea (21.5%) and pruritus (20.2%).<br \/>\n      The majority of adverse reactions reported for monotherapy were of Grade<br \/>\n      1 or 2 severity. The most serious adverse reactions were immune-related<br \/>\n      adverse reactions and severe infusion-related reactions.\n    <\/p>\n<p>\n      <b>About EORTC<\/b>\n    <\/p>\n<p>\n      European Organisation for Research and Treatment of Cancer (EORTC)<br \/>\n      conducts clinical research in cancer, defining new standards of practice<br \/>\n      for better treatment and care of cancer patients. EORTC network<br \/>\n      comprises more than 5,500 multidisciplinary collaborators in more than<br \/>\n      930 hospitals and institutions in 27 countries. Through translational<br \/>\n      and clinical research, EORTC offers an integrated approach to<br \/>\n      therapeutic strategies, drug evaluation programs, outcomes research and<br \/>\n      quality of life. For more information, visit <a href=\"https:\/\/www.eortc.org\/\" rel=\"nofollow\">www.eortc.org<\/a>.\n    <\/p>\n<p>\n      <b>About Melanoma in Europe<\/b>\n    <\/p>\n<p>\n      Melanoma is the most serious form of skin cancer and is characterized by<br \/>\n      the uncontrolled growth of pigment-producing cells. Worldwide, the<br \/>\n      incidence of melanoma has been increasing over the past four decades in<br \/>\n      many populations, and it is estimated that in 2018 there will be more<br \/>\n      than 287,000 new melanoma cases and over 60,000 people will die from the<br \/>\n      disease. In Europe, the five-year survival rate for advanced or<br \/>\n      metastatic melanoma (stage IV) is estimated to be about five to 22<br \/>\n      percent.\n    <\/p>\n<p>\n      <b>About Merck\u2019s Commitment to Melanoma<\/b>\n    <\/p>\n<p>\n      Merck\u2019s long-term commitment to melanoma includes a broad clinical<br \/>\n      development program studying KEYTRUDA as monotherapy and in combination<br \/>\n      with other novel mechanisms. The program, which is comprised of more<br \/>\n      than 4,500 patients across 10 Merck-sponsored clinical studies, is<br \/>\n      evaluating KEYTRUDA across most settings and stages of the disease.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection,<br \/>\n      100mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Merck has the industry\u2019s largest immuno-oncology clinical research<br \/>\n      program. There are currently more than 850 trials studying KEYTRUDA<br \/>\n      across a wide variety of cancers and treatment settings. The KEYTRUDA<br \/>\n      clinical program seeks to understand the role of KEYTRUDA across cancers<br \/>\n      and the factors that may predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including exploring several different<br \/>\n      biomarkers.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Indications and<br \/>\n      Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is<br \/>\n      indicated for the first-line treatment of patients with metastatic<br \/>\n      nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK<br \/>\n      genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with carboplatin and either paclitaxel or<br \/>\n      nab-paclitaxel, is indicated for the first-line treatment of patients<br \/>\n      with metastatic squamous NSCLC.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [Tumor Proportion Score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK<i> <\/i>genomic<br \/>\n      tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the treatment of patients<br \/>\n      with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as determined<br \/>\n      by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for the chemotherapy agents<br \/>\n      administered in combination with KEYTRUDA, as appropriate.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after 3 or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Primary Mediastinal Large B-Cell Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory primary mediastinal large B-cell lymphoma (PMBCL), or<br \/>\n      who have relapsed after 2 or more prior lines of therapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in confirmatory trials. KEYTRUDA is not recommended for<br \/>\n      the treatment of patients with PMBCL who require urgent cytoreductive<br \/>\n      therapy.\n    <\/p>\n<p>\n      In adults with PMBCL, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression. In pediatric<br \/>\n      patients with PMBCL, KEYTRUDA is administered at a dose of 2 mg\/kg (up<br \/>\n      to a maximum of 200 mg) every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who are not eligible<br \/>\n      for cisplatin-containing chemotherapy and whose tumors express PD-L1<br \/>\n      [Combined Positive Score (CPS) \u226510] as determined by an FDA-approved<br \/>\n      test, or in patients who are not eligible for any platinum-containing<br \/>\n      chemotherapy regardless of PD-L1 status. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who have disease<br \/>\n      progression during or following platinum-containing chemotherapy or<br \/>\n      within 12 months of neoadjuvant or adjuvant treatment with<br \/>\n      platinum-containing chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      children with MSI-H cancer, KEYTRUDA is administered at a dose of 2<br \/>\n      mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Gastric Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent<br \/>\n      locally advanced or metastatic gastric or gastroesophageal junction<br \/>\n      (GEJ) adenocarcinoma whose tumors express PD-L1 [Combined Positive Score<br \/>\n      (CPS) \u22651] as determined by an FDA-approved test, with disease<br \/>\n      progression on or after two or more prior lines of therapy including<br \/>\n      fluoropyrimidine- and platinum-containing chemotherapy and if<br \/>\n      appropriate, HER2\/neu-targeted therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. The recommended dose of KEYTRUDA is a fixed dose of<br \/>\n      200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Cervical Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic cervical cancer with disease progression on or after<br \/>\n      chemotherapy whose tumors express PD-L1 (CPS \u22651) as determined by an<br \/>\n      FDA-approved test. This indication is approved under accelerated<br \/>\n      approval based on tumor response rate and durability of response.<br \/>\n      Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials. The recommended dose of KEYTRUDA is a fixed dose of 200 mg every<br \/>\n      three weeks until disease progression, unacceptable toxicity, or up to<br \/>\n      24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Hepatocellular Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with hepatocellular<br \/>\n      carcinoma (HCC) who have been previously treated with sorafenib. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The recommended dose of<br \/>\n      KEYTRUDA is a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      <b>Immune-Mediated Pneumonitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 3.4% (94\/2799) of patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%),<br \/>\n      and occurred more frequently in patients with a history of prior<br \/>\n      thoracic radiation (6.9%) compared to those without (2.9%). Monitor<br \/>\n      patients for signs and symptoms of pneumonitis. Evaluate suspected<br \/>\n      pneumonitis with radiographic imaging. Administer corticosteroids for<br \/>\n      Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2;<br \/>\n      permanently discontinue KEYTRUDA for Grade 3 or 4 or recurrent Grade 2<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Colitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 1.7%<br \/>\n      (48\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%). Monitor patients for signs and symptoms of<br \/>\n      colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Hepatitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 0.7%<br \/>\n      (19\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%). Monitor patients for changes in liver function.<br \/>\n      Administer corticosteroids for Grade 2 or greater hepatitis and, based<br \/>\n      on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Immune-Mediated Endocrinopathies<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis, thyroid disorders, and type 1 diabetes<br \/>\n      mellitus. Hypophysitis occurred in 0.6% (17\/2799) of patients, including<br \/>\n      Grade 2 (0.2%), 3 (0.3%), and 4 (&lt;0.1%). Hypothyroidism occurred in 8.5%<br \/>\n      (237\/2799) of patients, including Grade 2 (6.2%) and 3 (0.1%). The<br \/>\n      incidence of new or worsening hypothyroidism was higher in patients with<br \/>\n      HNSCC occurring in 15% (28\/192) of patients. Hyperthyroidism occurred in<br \/>\n      3.4% (96\/2799) of patients, including Grade 2 (0.8%) and 3 (0.1%), and<br \/>\n      thyroiditis occurred in 0.6% (16\/2799) of patients, including Grade 2<br \/>\n      (0.3%). Type 1 diabetes mellitus, including diabetic ketoacidosis,<br \/>\n      occurred in 0.2% (6\/2799) of patients.\n    <\/p>\n<p>\n      Monitor patients for signs and symptoms of hypophysitis (including<br \/>\n      hypopituitarism and adrenal insufficiency), thyroid function (prior to<br \/>\n      and periodically during treatment), and hyperglycemia. For hypophysitis,<br \/>\n      administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2 and withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis. Administer hormone replacement for<br \/>\n      hypothyroidism and manage hyperthyroidism with thionamides and<br \/>\n      beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 hyperthyroidism. Administer insulin for type 1 diabetes, and<br \/>\n      withhold KEYTRUDA and administer antihyperglycemics in patients with<br \/>\n      severe hyperglycemia.\n    <\/p>\n<p>\n      <b>Immune-Mediated Nephritis and Renal Dysfunction<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 0.3%<br \/>\n      (9\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Nephritis occurred in 1.7% (7\/405) of<br \/>\n      patients receiving KEYTRUDA in combination with pemetrexed and platinum<br \/>\n      chemotherapy. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Skin Reactions<\/b>\n    <\/p>\n<p>\n      Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic<br \/>\n      epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative<br \/>\n      dermatitis, and bullous pemphigoid, can occur. Monitor patients for<br \/>\n      suspected severe skin reactions and based on the severity of the adverse<br \/>\n      reaction, withhold or permanently discontinue KEYTRUDA and administer<br \/>\n      corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA<br \/>\n      and refer the patient for specialized care for assessment and treatment.<br \/>\n      If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Other Immune-Mediated Adverse Reactions<\/b>\n    <\/p>\n<p>\n      Immune-mediated adverse reactions, which may be severe or fatal, can<br \/>\n      occur in any organ system or tissue in patients receiving KEYTRUDA and<br \/>\n      may also occur after discontinuation of treatment. For suspected<br \/>\n      immune-mediated adverse reactions, ensure adequate evaluation to confirm<br \/>\n      etiology or exclude other causes. Based on the severity of the adverse<br \/>\n      reaction, withhold KEYTRUDA and administer corticosteroids. Upon<br \/>\n      improvement to Grade 1 or less, initiate corticosteroid taper and<br \/>\n      continue to taper over at least 1 month. Based on limited data from<br \/>\n      clinical studies in patients whose immune-related adverse reactions<br \/>\n      could not be controlled with corticosteroid use, administration of other<br \/>\n      systemic immunosuppressants can be considered. Resume KEYTRUDA when the<br \/>\n      adverse reaction remains at Grade 1 or less following corticosteroid<br \/>\n      taper. Permanently discontinue KEYTRUDA for any Grade 3 immune-mediated<br \/>\n      adverse reaction that recurs and for any life-threatening<br \/>\n      immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, sarcoidosis, and<br \/>\n      encephalitis. In addition, myelitis and myocarditis were reported in<br \/>\n      other clinical trials and postmarketing use.\n    <\/p>\n<p>\n      Treatment with KEYTRUDA may increase the risk of rejection in solid<br \/>\n      organ transplant recipients. Consider the benefit of treatment vs the<br \/>\n      risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      <b>Infusion-Related Reactions<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 0.2% (6\/2799) of patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions. For Grade 3 or 4 reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Complications of Allogeneic Hematopoietic Stem Cell Transplantation<br \/>\n      (HSCT)<\/b>\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic HSCT after treatment with KEYTRUDA. Of<br \/>\n      23 patients with cHL who proceeded to allogeneic HSCT after KEYTRUDA, 6<br \/>\n      developed graft-versus-host disease (GVHD) (1 fatal case) and 2<br \/>\n      developed severe hepatic veno-occlusive disease (VOD) after<br \/>\n      reduced-intensity conditioning (1 fatal case). Cases of fatal hyperacute<br \/>\n      GVHD after allogeneic HSCT have also been reported in patients with<br \/>\n      lymphoma who received a PD-1 receptor\u2013blocking antibody before<br \/>\n      transplantation. Follow patients closely for early evidence of<br \/>\n      transplant-related complications such as hyperacute graft-versus-host<br \/>\n      disease (GVHD), Grade 3 to 4 acute GVHD, steroid-requiring febrile<br \/>\n      syndrome, hepatic veno-occlusive disease (VOD), and other<br \/>\n      immune-mediated adverse reactions.\n    <\/p>\n<p>\n      In patients with a history of allogeneic HSCT, acute GVHD (including<br \/>\n      fatal GVHD) has been reported after treatment with KEYTRUDA. Patients<br \/>\n      who experienced GVHD after their transplant procedure may be at<br \/>\n      increased risk for GVHD after KEYTRUDA. Consider the benefit of KEYTRUDA<br \/>\n      vs the risk of GVHD in these patients.\n    <\/p>\n<p>\n      <b>Increased Mortality in Patients With Multiple Myeloma<\/b>\n    <\/p>\n<p>\n      In clinical trials in patients with multiple myeloma, the addition of<br \/>\n      KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in<br \/>\n      increased mortality. Treatment of these patients with a PD-1 or PD-L1<br \/>\n      blocking antibody in this combination is not recommended outside of<br \/>\n      controlled clinical trials.\n    <\/p>\n<p>\n      <b>Embryofetal Toxicity<\/b>\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      <b>Adverse Reactions<\/b>\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      permanent discontinuation in more than one patient were colitis (1.4%),<br \/>\n      autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy<br \/>\n      (0.4%), and cardiac failure (0.4%). The most common adverse reactions<br \/>\n      (\u226520%) with KEYTRUDA were fatigue (28%), diarrhea (26%), rash (24%), and<br \/>\n      nausea (21%).\n    <\/p>\n<p>\n      In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and<br \/>\n      platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was<br \/>\n      discontinued due to adverse reactions in 20% of 405 patients. The most<br \/>\n      common adverse reactions resulting in permanent discontinuation of<br \/>\n      KEYTRUDA were pneumonitis (3%) and acute kidney injury (2%). The most<br \/>\n      common adverse reactions (\u226520%) with KEYTRUDA were nausea (56%), fatigue<br \/>\n      (56%), constipation (35%), diarrhea (31%), decreased appetite (28%),<br \/>\n      rash (25%), vomiting (24%), cough (21%), dyspnea (21%), and pyrexia<br \/>\n      (20%).\n    <\/p>\n<p>\n      In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and<br \/>\n      either paclitaxel or nab-paclitaxel in metastatic squamous NSCLC,<br \/>\n      KEYTRUDA was discontinued due to adverse reactions in 15% of 101<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were febrile neutropenia, pneumonia, and urinary<br \/>\n      tract infection. Adverse reactions observed in KEYNOTE-407 were similar<br \/>\n      to those observed in KEYNOTE-189 with the exception that increased<br \/>\n      incidences of alopecia (47% vs 36%) and peripheral neuropathy (31% vs<br \/>\n      25%) were observed in the KEYTRUDA and chemotherapy arm compared to the<br \/>\n      placebo and chemotherapy arm in KEYNOTE-407.\n    <\/p>\n<p>\n      In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse<br \/>\n      reactions in 8% of 682 patients with metastatic NSCLC. The most common<br \/>\n      adverse event resulting in permanent discontinuation of KEYTRUDA was<br \/>\n      pneumonitis (1.8%). The most common adverse reactions (\u226520%) were<br \/>\n      decreased appetite (25%), fatigue (25%), dyspnea (23%), and nausea (20%).\n    <\/p>\n<p>\n      In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      17% of 192 patients with HNSCC. Serious adverse reactions occurred in<br \/>\n      45% of patients. The most frequent serious adverse reactions reported in<br \/>\n      at least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (\u226520%) were fatigue, decreased appetite, and dyspnea.<br \/>\n      Adverse reactions occurring in patients with HNSCC were generally<br \/>\n      similar to those occurring in patients with melanoma or NSCLC who<br \/>\n      received KEYTRUDA as a monotherapy, with the exception of increased<br \/>\n      incidences of facial edema and new or worsening hypothyroidism.\n    <\/p>\n<p>\n      In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5%<br \/>\n      of 210 patients with cHL. Serious adverse reactions occurred in 16% of<br \/>\n      patients; those \u22651% included pneumonia, pneumonitis, pyrexia, dyspnea,<br \/>\n      GVHD, and herpes zoster. Two patients died from causes other than<br \/>\n      disease progression; 1 from GVHD after subsequent allogeneic HSCT and 1<br \/>\n      from septic shock. The most common adverse reactions (\u226520%) were fatigue<br \/>\n      (26%), pyrexia (24%), cough (24%), musculoskeletal pain (21%), diarrhea<br \/>\n      (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 53 patients with PMBCL. Serious adverse reactions occurred in 26% of<br \/>\n      patients and included arrhythmia (4%), cardiac tamponade (2%),<br \/>\n      myocardial infarction (2%), pericardial effusion (2%), and pericarditis<br \/>\n      (2%). Six (11%) patients died within 30 days of start of treatment. The<br \/>\n      most common adverse reactions (\u226520%) were musculoskeletal pain (30%),<br \/>\n      upper respiratory tract infection and pyrexia (28% each), cough (26%),<br \/>\n      fatigue (23%), and dyspnea (21%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      11% of 370 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. Serious adverse reactions occurred in 42% of patients; those<br \/>\n      \u22652% were urinary tract infection, hematuria, acute kidney injury,<br \/>\n      pneumonia, and urosepsis. The most common adverse reactions (\u226520%) were<br \/>\n      fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),<br \/>\n      constipation (21%), rash (21%), and diarrhea (20%).\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Serious adverse<br \/>\n      reactions occurred in 39% of KEYTRUDA-treated patients; those \u22652% were<br \/>\n      urinary tract infection, pneumonia, anemia, and pneumonitis. The most<br \/>\n      common adverse reactions (\u226520%) in patients who received KEYTRUDA were<br \/>\n      fatigue (38%), musculoskeletal pain (32%), pruritus (23%), decreased<br \/>\n      appetite (21%), nausea (21%), and rash (20%).\n    <\/p>\n<p>\n      Adverse reactions occurring in patients with gastric cancer were similar<br \/>\n      to those occurring in patients with melanoma or NSCLC who received<br \/>\n      KEYTRUDA as a monotherapy.\n    <\/p>\n<p>\n      In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 98 patients with recurrent or metastatic cervical cancer. Serious<br \/>\n      adverse reactions occurred in 39% of patients receiving KEYTRUDA; the<br \/>\n      most frequent included anemia (7%), fistula, hemorrhage, and infections<br \/>\n      [except urinary tract infections] (4.1% each). The most common adverse<br \/>\n      reactions (\u226520%) were fatigue (43%), musculoskeletal pain (27%),<br \/>\n      diarrhea (23%), pain and abdominal pain (22% each), and decreased<br \/>\n      appetite (21%).\n    <\/p>\n<p>\n      Adverse reactions occurring in patients with hepatocelluslar carcinoma<br \/>\n      (HCC) were generally similar to those in patients with melanoma or NSCLC<br \/>\n      who received KEYTRUDA as a monotherapy, with the exception of increased<br \/>\n      incidences of ascites (8% Grades 3-4) and immune-mediated hepatitis<br \/>\n      (2.9%). Laboratory abnormalities (Grades 3-4) that occurred at a higher<br \/>\n      incidence were elevated AST (20%), ALT (9%), and hyperbilirubinemia<br \/>\n      (10%).\n    <\/p>\n<p>\n      <b>Lactation<\/b>\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use<\/b>\n    <\/p>\n<p>\n      There is limited experience in pediatric patients. In a study in 40<br \/>\n      pediatric patients with advanced melanoma, lymphoma, or PD-L1\u2013positive<br \/>\n      advanced, relapsed, or refractory solid tumors, the safety profile was<br \/>\n      similar to that seen in adults treated with KEYTRUDA. Toxicities that<br \/>\n      occurred at a higher rate (\u226515% difference) in these patients when<br \/>\n      compared to adults under 65 years of age were fatigue (45%), vomiting<br \/>\n      (38%), abdominal pain (28%), hypertransaminasemia (28%), and<br \/>\n      hyponatremia (18%).\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, the potential<br \/>\n      to bring new hope to people with cancer drives our purpose and<br \/>\n      supporting accessibility to our cancer medicines is our commitment. As<br \/>\n      part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the largest development<br \/>\n      programs in the industry across more than 30 tumor types. We also<br \/>\n      continue to strengthen our portfolio through strategic acquisitions and<br \/>\n      are prioritizing the development of several promising oncology<br \/>\n      candidates with the potential to improve the treatment of advanced<br \/>\n      cancers. For more information about our oncology clinical trials, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/clinicaltrials\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and&nbsp;connect<br \/>\n      with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"https:\/\/www.youtube.com\/user\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media Contacts:<br \/>Pamela Eisele<br \/>(267) 305-3558<br \/>or<br \/>Elizabeth        Sell<br \/>(267) 305-3877<br \/>or<br \/>Investor Contacts:<br \/>Teri Loxam<br \/>(908)        740-1986<br \/>or<br \/>Michael DeCarbo<br \/>(908) 740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, the company\u2019s anti-PD-1 therapy, for the adjuvant treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection. This approval is based on data from the pivotal Phase 3 EORTC1325\/KEYNOTE-054 trial, conducted in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC). An updated recurrence-free survival (RFS) data analysis, conducted at the request of the European Medicines Agency, demonstrated that KEYTRUDA significantly prolonged RFS, reducing the risk of disease recurrence or death by 44 percent compared to placebo in the overall population of patients with resected, high-risk stage III melanoma (HR=0.56; 98% CI, 0.44-0.72; p&lt;0.0001). \u201cMerck\u2019s long-term commitment to melanoma patients includes a particular focus on bringing new treatment options to these patients<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745626","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, the company\u2019s anti-PD-1 therapy, for the adjuvant treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection. This approval is based on data from the pivotal Phase 3 EORTC1325\/KEYNOTE-054 trial, conducted in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC). An updated recurrence-free survival (RFS) data analysis, conducted at the request of the European Medicines Agency, demonstrated that KEYTRUDA significantly prolonged RFS, reducing the risk of disease recurrence or death by 44 percent compared to placebo in the overall population of patients with resected, high-risk stage III melanoma (HR=0.56; 98% CI, 0.44-0.72; p&lt;0.0001). \u201cMerck\u2019s long-term commitment to melanoma patients includes a particular focus on bringing new treatment options to these patients\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"25 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\\\/\",\"name\":\"European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2018-12-17T06:30:00+00:00\",\"dateModified\":\"2025-11-07T06:26:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\/","og_locale":"en_US","og_type":"article","og_title":"European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, the company\u2019s anti-PD-1 therapy, for the adjuvant treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection. This approval is based on data from the pivotal Phase 3 EORTC1325\/KEYNOTE-054 trial, conducted in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC). An updated recurrence-free survival (RFS) data analysis, conducted at the request of the European Medicines Agency, demonstrated that KEYTRUDA significantly prolonged RFS, reducing the risk of disease recurrence or death by 44 percent compared to placebo in the overall population of patients with resected, high-risk stage III melanoma (HR=0.56; 98% CI, 0.44-0.72; p&lt;0.0001). \u201cMerck\u2019s long-term commitment to melanoma patients includes a particular focus on bringing new treatment options to these patients","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:50+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"25 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\/","name":"European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2018-12-17T06:30:00+00:00","dateModified":"2025-11-07T06:26:50+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"c08c1be8-2954-497a-bfab-96e1af4d5467","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/European-Commission-Approves-Mercks-KEYTRUDA-pembrolizumab-as-Adjuvant-Therapy-for-Adults-with-Resected-Stage-III-Melanoma-2018.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745626\/revisions"}],"predecessor-version":[{"id":3674982,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745626\/revisions\/3674982"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745626"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}